Skip to content
PIL Logo

Bambec Tablets 10mg & 20mg

Last Updated on eMC 12-Jun-2017 View document  | AstraZeneca UK Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 12-Jun-2017 and displayed until Current

Reasons for adding or updating:

  • Change to section 5 - how to store or dispose
  • Change to section 6 - date of revision
  • Improved presentation of PIL

Updated on 21-Jun-2016 and displayed until 12-Jun-2017

Reasons for adding or updating:

  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 3 - how to take/use
  • Change to section 6 - date of revision

Updated on 29-Aug-2014 and displayed until 21-Jun-2016

Reasons for adding or updating:

  • Change to section 1 - what the product is
  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - driving and using machines
  • Change to section 2 - excipient warnings
  • Change to section 3 - use in children/adolescents
  • Change to section 3 - how to take/use
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 5 - how to store
  • Change to section 6 - what the product contains
  • Change to section 6 - date of revision

Updated on 23-Mar-2011 and displayed until 29-Aug-2014

Reasons for adding or updating:

  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 02-Jul-2009 and displayed until 23-Mar-2011

Reasons for adding or updating:

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 19-Oct-2007 and displayed until 02-Jul-2009

Reasons for adding or updating:

  • Change due to user-testing of patient information

Updated on 26-Nov-2003 and displayed until 19-Oct-2007

Reasons for adding or updating:

  • Update to PIL

Updated on 04-Sep-2002 and displayed until 26-Nov-2003

Reasons for adding or updating:

  • Update to PIL

Updated on 17-Jun-2002 and displayed until 04-Sep-2002

Reasons for adding or updating:

  • New PIL for eMC ie a PIL for an existing product but new to the eMC

Company contact details

AstraZeneca UK Limited

Company image
Address

Horizon Place, 600 Capability Green, Luton, Bedfordshire, LU1 3LU

Fax

+44 (0)1582 838 000

Medical Information e-mail
Medical Information Fax

+44 (0)1582 838 003

Telephone

+44 (0)1582 836 000

Medical Information Direct Line

0800 783 0033

Customer Care direct line

+44 (0)1582 837 837

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

bambuterol hydrochloride

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue